Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Acetoacetic acid sodium salt is a metabolite of non-esterified fatty acids, involved in the development of human diabetes.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,500 | |||
2 mg | 在庫あり | ¥ 13,500 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 34,000 | |||
25 mg | 在庫あり | ¥ 55,000 | |||
50 mg | 在庫あり | ¥ 83,000 | |||
100 mg | 在庫あり | ¥ 123,000 | |||
500 mg | 在庫あり | ¥ 266,500 |
説明 | Acetoacetic acid sodium salt is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. |
In vitro | Acetoacetic acid sodium salt triggers oxidative stress, thereby impeding very-low-density lipoprotein (VLDL) assembly in bovine hepatocytes. This compound, at concentrations of 0.6, 2.4, and 4.8 mM, increases malondialdehyde (MDA) content in the high-dose group (GH), diminishes mRNA levels of Mn-SOD, Cu/Zn SOD, and glutathione peroxidase (GSH-Px) across all groups, and reduces catalase (CAT) mRNA expression in the medial-dose (GM) and GH groups. Furthermore, it suppresses mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and the low-density lipoprotein receptor (LDLR), leading to reduced VLDL assembly and heightened triglyceride (TG) accumulation in bovine hepatocytes. |
分子量 | 124.07 |
分子式 | C4H5NaO3 |
CAS No. | 623-58-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (403.00 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Acetoacetic acid sodium salt 623-58-5 Others inhibit Endogenous Metabolite Acetoacetic acid sodium Inhibitor Acetoacetic acid inhibitor